US EditionPublished • loading... • Updated
US Lung Cancer Patient Stabilized by China-Only Immunotherapy
Ivonescimab, the first approved PD-1/VEGF bispecific antibody, stabilized a U.S. lung cancer patient after standard treatments failed, despite ICU complications during care.
- Jiahui International Cancer Center stabilized a U.S. patient with advanced non-small cell lung cancer using ivonescimab, a new immunotherapy available only in China.
- The patient had used all standard treatments at MD Anderson Cancer Center in the U.S. before starting ivonescimab therapy.
- Ivonescimab is the first approved PD-1/VEGF bispecific antibody for solid tumors and was recommended by the patient's doctors.
- Despite immune-related complications during treatment, the patient's condition stabilized and ongoing care focuses on disease control.
Insights by Ground AI
61 Articles
61 Articles
Coverage Details
Total News Sources61
Leaning Left8Leaning Right9Center23Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 20%
C 58%
R 22%
Factuality
To view factuality data please Upgrade to Premium
